Netflix Stock Price Soars After Earnings Report Record New Memberships
Netflix stock price ( NASDAQ: NFLX ) is up more than 13% in the after-hours following its release of the fourth-quarter earnings report for fiscal year 2024. The streaming company recorded a 16% increase in revenue year-over-year, reaching 19% on a foreign exchange (F/X) neutral basis, which the
If you invested $1000 in Chipotle Mexican Grill (NYSE:CMG) 5 years ago, here's how much it's worth today
They say, “If it looks like a restaurant, cooks food like a restaurant, and serves food like a restaurant, then it’s probably a restaurant.”. However, this might not be how investors see Chipotle Mexican Grill ( NYSE:CMG ). Chipotle’s stock is currently trading at a P/E ratio of around 54, while many
ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025
GlobeNewswire Inc.
50 minutes ago
Systemic activity of 35% ORR in 2L+ patients, including in patients with active brain metastases Manageable safety profile with low discontinuation rate Enrollment completed; no further development planned in this patient population Company to host
Canadian Natural Resources Limited Prices C$1,650 Million in 3, 5 and 10 Year Medium-Term Notes
Newsfile
2 hours ago
Calgary, Alberta--(Newsfile Corp. - December 4, 2025) - Canadian Natural Resources Limited (TSX: CNQ) (NYSE: CNQ) ("Canadian Natural" or the "Company") announces that on December 4, 2025, it priced the following medium-term notes ("Notes") which were
31% of Expert Network Calls Include Experts Who Say They Weren't Fully Qualified, Landmark Woozle Research Study Finds
Newsfile
3 hours ago
A new study by Woozle Research surveyed 1,368 expert network participants and found significant concerns around project matching, AI-moderated consultations, and compensation practices. The findings suggest systemic issues across the expert network i
Symbotic Announces Pricing of Primary and Secondary Offering of Class A Common Stock
GlobeNewswire Inc.
3 hours ago
WILMINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Symbotic Inc. (Nasdaq: SYM), a leader in A.I.-enabled robotics technology for the supply chain, today announced the pricing of its previously announced underwritten public offering (the “Offering
Protara Announces Pricing of $75 Million Public Offering
GlobeNewswire Inc.
3 hours ago
NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the pricing of its underw
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025
GlobeNewswire Inc.
4 hours ago
Highly differentiated 1L EGFR PACC preliminary systemic activity of 80% ORR and 100% intracranial ORR, including in patients with active brain metastases 36% ORR in median 3L EGFR PACC patients exceeds competitor benchmarks Competitive safety profile
J2 Metals Inc. Announces Shareholder Approval for Spin-Out
Newsfile
4 hours ago
Vancouver, British Columbia--(Newsfile Corp. - December 4, 2025) - J2 Metals Inc. (TSXV: JTWO) ("J2" or the "Company") is pleased to announce that the Company's shareholders ("Shareholders") approved the plan of arrangement (the "Arrangement") with T
Alsona Unveils the First Curated LinkedIn Expert Directory
Newsfile
5 hours ago
Newark, Delaware--(Newsfile Corp. - December 4, 2025) - Alsona introduces a first-of-its-kind curated platform featuring verified specialists in LinkedIn growth, profile optimization, lead generation, and content strategy, designed to help profession
CAT Strategic Metals Announces Rights Offering Closing
Newsfile
5 hours ago
Vancouver, British Columbia--(Newsfile Corp. - December 4, 2025) - CAT Strategic Metals Corporation (CSE: CAT) (OTC Pink: CATTF) (FSE: 8CHA) ("CAT" or the "Company") is pleased to announce the closing of its previously announced rights offering on No
Transcenta Therapeutics Presents Updated Efficacy Data from the Phase I/II Transtar102 Trial of Osemitamab plus Nivolumab and CAPOX in First-Line G/GEJ Cancer at ESMO Asia
GlobeNewswire Inc.
5 hours ago
Data showed encouraging results in patients with higher CLDN18.2 expression regardless of PD-L1 expression level, with a median PFS of 16.6 months, ORR of 68% and median DoR of 18 monthsPRINCETON, N.J. and SUZHOU, China, Dec. 04, 2025 (GLOBE NEWSWI
